About the Authors

Martin Farrall, John F Peden, Hugh Watkins
Department of Cardiovascular Medicine, University of Oxford, Oxford, United Kingdom

Fiona R Green
School of Biomedical and Molecular Sciences, University of Surrey, Guildford, United Kingdom

Per G Olsson, Gunnar Olsson
AstraZeneca AB, Mölndal, Sweden

Robert Clarke, Rory Collins
Clinical Trials Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, United Kingdom

Mai-Lis Hellenius, Jacob Lagercrantz, Anders Hamsten
Department of Medicine, Karolinska Institute, Stockholm, Sweden

Stephan Rust, Helmut Schulte, Gerd Assmann
Leibniz—Institut für Arterioskleroseforschung an der Universität Münster, Münster, Germany

Maria Grazia Franzosi, Gianni Tognoni
Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy

Alisoun Carey
Oxagen Limited, Abingdon, Oxfordshire, United Kingdom

Gerd Assmann
Institute for Clinical Chemistry and Laboratory Medicine, University Clinics Münster, Münster, Germany

Corresponding Author

hugh.watkins@cardiov.ox.ac.uk

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

MF, FRG, JFP, PGO, RC, MLH, SR, JL, MGF, HS, AC, GO, GA, GT, RC, AH, and HW conceived and designed the experiments. MF, JFP, RC, and HW analyzed the data. MF, PGO, RC, MLH, SR, JL, MGF, HS, AC, GO, GA, GT, RC, and AH contributed reagents/materials/analysis tools. MF, FRG, JFP, and HW wrote the paper.